Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: Comparison of aliskiren, irbesartan and ramipril

International Journal of Clinical Practice

Volumn 65, Issue 2, 2011, Pages 127-133

  Burnier, M ^a   Brede, Y ^b   Lowy, A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; IRBESARTAN; RAMIPRIL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; RAMIPRIL; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 78751563288     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02616.x     Document Type: Article

References (41)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.
2. Bombardier C, Maetzel A,. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999; 58 (Suppl. 1): I82-5.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
4. Vrijens B G V, Kristanto P, Urquhart J, Burnier M,. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-17.
5. Taylor AA, Shoheiber O,. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 324-32.
6. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR,. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc 2009; 101: 34-9.
7. Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF,. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 2008; 18: 302-9.
8. Kannel WB,. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-6.
9. Urquhart J,. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17 (Suppl. A): 8-15.
10. Urquhart J,. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207-19.
11. Smilde JG,. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res 1997; 58: 141-53.
12. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL,. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
13. Lowy A, Munk VC, Ong SH, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract, 2010; 65: 41-53.
14. Novartis Pharmaceuticals Corporation. 2007 Data on file.
15. Anderson KM, Odell PM, Wilson PW, Kannel WB,. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293-8.
16. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS,. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-30.
17. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48: 418-25.
18. Bloom BS,. Daily regimen and compliance with treatment. BMJ 2001; 323: 647.
19. Morgan SG, Yan L,. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol 2004; 11: e267-73.
20. Schroeder K, Fahey T, Ebrahim S,. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722-32.
21. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F,. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003; 9: 424-9.
22. Thaker D, Frech F, Gause D, Zhang W,. Patient compliance and persistency with antihypertensive agents: A comparison of agents in different therapeutic classes. Am J Hypertens 2005; 18: 222A. (Abstract P-589).
23. Hoer A, Gothe H, Khan ZM, Schiffhorst G, Vincze G, Haussler B,. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens 2007; 21: 744-6.
24. Svensson S, Kjellgren KI, Ahlner J, Saljo R,. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000; 76: 157-63.
25. Burnier M,. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-6.
26. Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther 2001; 23: 715-26.
27. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483-9.
28. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in over 12,000 patients with hypertension. J Clin Hypertens 2010; 12: 765-75.
29. Frampton JE, Curran MP,. Aliskiren: A review of its use in the management of hypertension. Drugs 2007; 67: 1767-92.
30. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A,. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9.
31. Krone W, Hanefeld M, Meyer HF, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2010; Apr 8. [Epub ahead of print].
32. National Health and Nutrition Examination Survey. 2005-2006 Demographics File: Demographics. In; 2009.
33. National Health and Nutrition Examination Survey. 2005-2006 Examination File: Blood Pressure. In; 2009.
34. National Health and Nutrition Examination Survey. 2005-2006 Examination File: Body measurements. In; 2009.
35. National Health and Nutrition Examination Survey. 2005-2006 Questionnaire Files: Smoking-Cigarette Use. In; 2009.
36. National Health and Nutrition Examination Survey. 2005-2006 Questionnaire Files: Diabetes. In; 2009.
37. National Health and Nutrition Examination Survey. 2005-2006 Laboratory Files: HDL Cholesterol. In; 2009.
38. National Health and Nutrition Examination Survey. 2005-2006 Laboratory Files: Total Cholesterol. In; 2009.
39. Anderson KM, Wilson PW, Odell PM, Kannel WB,. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
40. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
41. National Health and Nutrition Examination Survey. 2005-2006 Laboratory Files: Glycohemoglobin. In; 2009.